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Carcinoma of the breast is the most common cause of cancer in women in Western society. Although breast cancer occurs 
predominantly in older premenopausal and postmenopausal women, it also occurs in young women. Literature defines breast 
cancer in a young woman (or early onset breast cancer) as occurring in a woman less than 35 years of age. A diagnosis of 
breast cancer in a young woman impacts severely on all aspects of her life, as well as on those around her.
In Africa and other developing countries, the breast cancer burden is increasing and poor reporting and data availability may 
underestimate the exact numbers. The average age of diagnosis may be younger for women in developing countries than for 
women in developed countries. African patients are more likely to be premenopausal at diagnosis and the breast cancers tend 
to be more advanced at presentation than in other population groups in a country such as South Africa.
The choice of surgical treatment in early onset cancer depends on various factors. Young age is an independent risk factor 
for worse outcome regardless of whether a patient had a mastectomy or breast conserving therapy. Breast conserving treat-
ment is an option for treatment of breast cancer in a young patient given the correct indications and that the patient is fully 
informed about the high risk of local recurrence.
The extent of genetic factors such as mutations on BRCA 1 and 2 (BReast CAncer 1 and 2) genes is still largely unknown 
on the continent of Africa, and much research still needs to be done. In the USA, only 5-10% of early onset breast cancers are 
attributable to mutations on BRCA 1 and 2 genes, and another 15-20% of early onset breast cancers are due to gene polimor-
phisms and environmental factors.
General breast awareness among women of all age groups in Africa should be promoted. This includes how to perform self 
breast examinations and to seek urgent medical attention when a breast lump is discovered. In time, given the resources, good 
screening programmes on this continent to detect breast cancer at its earliest presentation would be the ideal.
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Introduction
In Western society and the world over, 
carcinoma of the breast is the most 
common cause of cancer in women.17 
In South Africa, between 1993 and 
1995 it has overtaken cervical cancer as 
the most common cancer in women.15 
Breast cancer is mostly regarded as 
a disease occurring predominantly in 
older premenopausal and postmeno-
pausal women. Much focus has been 
placed on these two groups of women 
over the years. However, breast cancer 
does occur in young women. In the Unit-
ed States, 2.7 % of patients with breast 
cancer are younger than 35 years.13 It is 
reported that in the United States the in-
cidence in women 20-24 years of age is 
1.4 per 100,000 women, and for women 
aged 25-29 years 8.1 per 100,000 
women. In women between the ages of 
30-34 years, the incidence increases to 
24.8 per 100,000 women.13
Although a relatively rare disease in 
young women, a diagnosis of breast 
cancer impacts severely on the young 
patient’s life and future, extending to her 
family and society as a whole. It also im-
pacts on the medical personnel involved 
in her treatment and care giving. 
It has been shown that in young 
women, breast cancer has more ag-
gressive biological features1,6 with more 
advanced disease at diagnosis13 and a 
poorer prognosis (especially in the < 30 
years age group) than older premeno-
pausal patients.13 Much research still 
needs to be done on various aspects 
of breast cancer in this young popula-
tion. Interesting topics arise, such as 
the contribution of BRCA 1 and 2 germ 
line mutations in this young population, 
as well as other genetic influences and 
factors. Another topic, mastectomy 
versus breast conservation therapy in 
treatment of the patient with early onset 
breast cancer, from the perspective of 
Africa as a developing continent, will be 
examined in this article through existing 
literature and available data.
Breast cancer incidence rates in Africa 
as a developing continent.
The breast cancer burden is increasing 
in developing countries. It is estimated 
that 70% of new cancer cases will occur 
in inhabitants of developing countries by 
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the year 2020, and a vast number these 
cancers occurring in females will be of 
the breast.5,10 There are differences in 
the breast cancer incidence and mortal-
ity rates in the different geographical ar-
eas of the continent. This may be due to 
poor reporting and data availability, dif-
ficulty in estimating population denom-
inators or different ethnic compounds 
from region to region.5 In developing 
countries, the average age at diagnosis 
of breast cancer may be younger than in 
developed countries, as data from east-
ern populations suggest.7,12,14  
In eastern Africa, it is estimated that 
the age standardised incidence rates 
(per 100,000 women) is 19.5 .9 In west-
ern Africa it is 27.8, in middle Africa 16.5 
and 33.4 in southern Africa.9 Focusing 
on a country such as South Africa, the 
population consists of different ethnic 
groups. It is estimated that the lifetime 
risk for breast cancer in the white pop-
ulation of Anglo-European ancestry is 1/
13 comparable with rates in other west-
ern countries.15 In women of mixed eth-
nicity there is a 1/63 lifetime risk of de-
veloping breast cancer, in Asian wom-
en (mainly of Indian origin) there is 1/21 
risk and in black South African women it 
is 1/81 lifetime risk of developing breast 
cancer.15 Statistics are available through 
the National Cancer Registry, that re-
ports cancers diagnosed by histology, 
cytology and haematology laboratories 
in South Africa..2 The statistics may un-
derestimate the cancer burden.15 
It is estimated that the incidence is 
rising in the urban black African popu-
lation. Walker AR et al found in a study 
that during the period 1994-1999, look-
ing at hospital admissions of urban pa-
tients in Durban, the age adjusted annu-
al incidence of breast cancer was 15.1/
100,000 women, compared to previ-
ous figures of 5-10/100,000 for the ru-
ral black population.16 Another study 
reported a doubling of breast cancer 
rates in women living in urban areas 
in the Western Cape compared with 
their rural neighbours.8 There are cer-
tain factors in the rural African popula-
tion that lower the lifetime breast cancer 
risk. Late menarche, early age at birth of 
first child, multiparity and extended lac-
tation all result in fewer ovulatory cycles, 
with lower endogenous oestrogen lev-
els during a woman’s lifetime.5,15,16 Other 
protective factors such as being phys-
ically active, a diet rich in vegetables 
and grains, and low alcohol consump-
tion are cited as benefits of the rural life-
style.5,15,16 With urbanisation, the West-
ern lifestyle is frequently adopted, and 
thus the differences in incidence rates 
of breast cancer.
Of importance is the fact that African 
patients are more likely to be premeno-
pausal when diagnosed with breast 
cancer5 and present with breast cancer 
almost a decade earlier than their West-
ern counterparts.17 Breast cancer inci-
dence is highest between the ages of 
35-45 years in western Africa.5 
Breast cancer in the African popu-
lation has also shown to be more ad-
vanced at presentation than in oth-
er population groups. Seventy to nine-
ty per cent of African women of all age 
groups are diagnosed with breast can-
cer at stage III or IV.5 Vorobiof et al 
showed that 77.7% of stages 3 and 4 
breast cancer were found in black wom-
en, compared to 30.7%  in non black 
women, looking at medical records from 
several provincial hospitals from 1970-
1997.15 This is somewhat explained by a 
delay in seeking medical attention. It is 
also postulated that the tumour biology 
may be inherently more aggressive.5
A need for breast health awareness 
from an early age is vital. An investiga-
tion done to establish the awareness 
of breast and cervical cancers among 
women of African descent in rural and 
urban South Africa, published in 2002, 
showed that  one fifth of the respondents 
had not heard of these cancers and one 
third did not know about tests for breast 
cancer. Breast self examination tech-
niques were only known by half of the 
population studied.11 
Mastectomy versus breast conserv-
ing treatment in early onset breast 
cancer
In a young patient with breast cancer, 
breast conserving treatment (BCT) is 
obviously a choice that is cosmetical-
ly desirable. In deciding which treat-
ment option is best for a given patient, it 
is important to consider various factors. 
Young age is an independent risk factor 
for worse outcome in breast cancer re-
gardless of whether the patient had BCT 
or a mastectomy. The young age risk 
factor is independent of clinical tumour 
size, clinical lymph node status, histo-
logical grade, hormone receptor status 
and systemic treatment.18
Young age (< 35 years) is a risk fac-
tor for local recurrence after BCT, com-
pared to older patients who had BCT. 
Voogd et al found that women < 35years 
had a 9 times increased risk of local re-
currence after BCT than women old-
er than 60 years. Young patients who 
were treated with mastectomy had lo-
cal recurrence rates similar to their older 
counterparts who were also treated with 
mastectomy. Other risk factors for local 
recurrence after BCT in all age groups 
were infiltrating tumour with an exten-
sive intraductal component, vascular in-
vasion and involvement of excision mar-
gins.13
Conservative surgery without radio-
therapy was shown in various studies 
to have higher local recurrence rates in 
women with early onset cancer.18 In the 
EORTC (European Organisation for Re-
search and Treatment fo Cancer) “boost 
versus no boost” randomised trial, lo-
cal failure rate was reduced from 20% 
to 10% in patients < 40 years of age, a 
more pronounced result compared with 
patients > 50 years.
All patients with adjuvant systemic 
therapy, in the form of chemotherapy 
or hormonal therapy or both, have low-
er local recurrence rates after BCT. This 
applies to women of all age groups, al-
though it is unknown to what degree lo-
cal recurrence rates are reduced in 
women < 35 years of age.18 
The margin status of an excised tu-
mour is regarded as an important fac-
tor in local failure in all age groups. Wide 
surgical excision and negative histolog-
ical margins should reduce the local re-
currence rate.18 It has been found in the 
EORTC trial that young patients were 
found to have more DCIS (ductal carci-
noma in situ), and that it was often of a 
higher grade.18  
In a clinic based series of Robson et 
al of women with BRCA 1 and 2 who un-
derwent breast conserving treatment, 
the risk of ipsilateral breast cancer was 
the same as for women without known 
mutations. But due to the lifetime risk of 
contralateral breast cancer and late ip-
silateral breast cancer, bilateral mastec-
tomy as prophylaxis should be a serious 
consideration.12  
Breast conserving treatment need 
not be ruled out as a treatment option 
for young women in the developed or 
developing world, as long as the pa-
tient is fully aware of the high risk for lo-
cal recurrence. There are no studies that 
show that overall survival is negatively 
impacted in patients receiving BCT.13  
Genetic factors and early onset can-
cer
In the USA, only 5-10% of early onset 
breast cancers are attributable to germ 
line mutations such as BRCA 1 on chro-
mosome 17 and BRCA 2 on chromo-
some 13.4,6 Mutation rates are higher 
in patients with a strong family history 
ranging from 16-26% in BRCA 1 and 7-
13% in BRCA 2.4  In patients with BRCA 
1 mutation, there is a 50% chance of de-
veloping breast cancer by age 50, and 
an 80% chance by 70 years of age.13 
The lifetime risk for ovarian cancer in 
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these patients is 1 in 2. Breast cancer 
in BRCA 1 gene carriers is more likely 
grade 2 and 3, oestrogen and proges-
terone receptor negative, and HER 2 
negative.3 Also, 13% of these cancers 
are described as medullary or atypical 
medullary, compared to 1-3% of breast 
cancers described in routine practice.3 
Breast cancers due to BRCA 2 gene 
mutation are less distinctive, but 80% 
of these tumours are oestrogen recep-
tor positive.3 In African ancestry, breast 
cancer is less common, but it occurs at 
an earlier age and is more aggressive. 
Fackenthal et al analysed 39 young Ni-
gerian breast cancer patients and found 
that 74% carried at least one BRCA 1 
and 2 variation with 69% having se-
quence variation in BRCA 2, represen-
ting a higher frequency of BRCA 2 vari-
ants compared to a previously studied 
white cohort.4 It is proposed that the sig-
nificant genetic variation in BRCA 1 and 
2 may contribute to breast cancer risk. 
No founder mutation was identified in 
this study. The extent of the contribution 
of BRCA 1 and 2 to the breast cancer 
burden in Africa is uncertain.5,15,4 
Another 15-20% of breast cancers 
in young women are associated with 
gene polimorphisms and environmen-
tal factors, and the rest of the remaining 
breast cancer cases are thought to be 
sporadic.6 There are other rare genet-
ic causes that predispose young wom-
en to breast cancer. Li- Fraumeni syn-
drome is a mutation of the TP53 gene on 
chromosome 17. It is dominantly inhe-
rited, and causes paediatric soft tissue 
and bone sarcomas, leukaemia, brain, 
lung and adrenal cortical cancer, and 
breast cancer.13,6 Cowden syndrome is 
caused by a PTEN (phosphatase and 
tensin homoloque) gene mutation on 
chromosome 10, and the disease is as-
sociated with multiple hamartomas, and 
breast and thyroid cancer at a young 
age.13,6 Also, previous radiation during 
childhood and teenage years puts a 
young woman at higher risk for develo-
ping breast cancer.
Conclusion
Breast cancer does occur in young 
patients in Africa, a developing world. 
There is still much research to be done 
and accurate data collection needed on 
various aspects of early onset breast 
cancer in all regions of the continent. 
Breast conservation therapy is an op-
tion for treatment of breast cancer in the 
young patient given the correct indica-
tions. The extent of genetic factors such 
as mutations on BRCA 1 and 2 genes 
are still largely unknown on the continent 
of Africa. Hopefully, in the future, collab-
oration the world over will result in more 
knowledge of genetic factors, incidence 
and treatment of early onset breast can-
cer. General breast awareness among 
women of all age groups in Africa 
should be promoted, which includes 
breast-feeding and breast health: self 
breast examination must be taught and 
all women urged not to hesitate to visit 
a doctor if she discovers a breast lump, 
given that there are medical facilities 
close by. Screening programmes to de-
tect breast cancer at its earliest presen-
tation in women 40 years and older, from 
all socio-economic groups, would be 
an ideal. Unfortunately, on a continent 
where daily survival is a battle amidst 
violence, poverty and poor resources, 
hunger and AIDS, it is probably an unat-
tainable dream for the moment.
See CPD Questionnaire, page 42
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Points to ponder:
A young woman with a palpable breast lump should be sent for further investigation:
• Patients should be made aware of breast health from a young age.
• Encourage patients to go for annual mammograms from age 40. If cost is a 
     problem, at least then a mammogram every 2 years.
• If the woman’s mother had breast cancer at age 40, she should start screening 
     ten years earlier. A specialised breast health centre can also do a genetic risk 
     assessment for her.
• < age 25 Breast ultrasound plus an FNA (fine needle aspiration) of mass if confirmed.
• > age 25 Breast ultrasound plus a mammogram if indicated and FNA/needle core biopsy of mass if confirmed.
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Case study 1:  
A 34 year old female patient presented with a palpable lump in her right breast first felt a month previously. Clinically the 
mass was at 8h00, 2 cm from the nipple in the right breast, and it felt firm, mobile, 2 x 2 cm in diameter. Mammogram showed 
pleomorphic calcifications right inferolateral in the area of the mass (Figures 1, 2 and 3). Ultrasound showed an oval hy-
poechoic mass, poorly circumscribed (Figure 4). FNA (fine needle aspiration) was done under ultrasound guidance and cy-
tology was highly suspicious of malignancy. A needle core biopsy was done under ultrasound guidance to confirm the diag-
nosis and histology was compatible with invasive ductal carcinoma. 
Figure 4:  Ultrasound image of the lesion in the right breast: oval 
nonhomogeneous mass with mixed hypo- and hypere-
chogenicity and ill defined margins. Histology compati-
ble with invasive ductal carcinoma.
Figure 1:  Full field digital mammogram CC (cranio-caudal) view 
right breast: a group of pleomorphic micro calcifications 
noted inferolateral in area of palpable mass.
Figure 2:  Full field digital mammogram MLO (mediolateral oblique) 
view of the right breast: a group of pleomorphic micro 
calcifications inferolateral in the area of the palpable 
mass.
Figure 3:  Full field digital mammogram spot magnification CC 
(cranio-caudal) view of the right breast: the group of 
pleomorphic micro calcifications inferolateral clearly vis-
ible.
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Case Study 2:
A 30 year old female patient presented with a mass in the left breast present for the past 5 months. On examination the 
mass was palpable, 2 x 2 cm in the left breast at 5h00. Mammogram showed a spiculated lesion inferolateral left breast. 
See Figures 5 and 6. Ultrasound showed a nonhomogeneous hypoechoic lesion with poorly defined margins and posterior 
acoustic shadowing. See Figure 7. FNA (fine needle aspiration) was done under ultrasound guidance and cytology showed 
hyperplastic ductal epithelial cells, but the lesion looked suspicious on mammogram and ultrasound, and a needlecore 
biopsy or excision biopsy had to be done. The patient chose an excision biopsy, and histology confirmed classic invasive 
lobular carcinoma. 
Figure 5:  Full field digital mammogram MLO (mediolateral oblique) 
view of the left breast: spiculated mass inferolateral.
Figure 6:   Full field digital mammogram CC (cranio-caudal) view of 
the left breast: spiculated mass infero-lateral.
Figure 7:  Ultrasound image of the palpable lesion in the left breast: 
nonhomogeneous hypoechoic mass with irregular con-
tours, ill defined margins and posterior acoustic shadow-
ing. Histology compatible with invasive lobular carcinoma.
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